Daré Bioscience (DARE) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting of Stockholders scheduled for June 12, 2025, at 9:00 a.m. Pacific Time, to be held virtually.
Shareholders are encouraged to review proxy materials and vote by June 11, 2025.
Voting matters and shareholder proposals
Election of three Class II Directors: William H. Rastetter, Gregory W. Matz, and Robin J. Steele.
Ratification of Haskell & White, LLP as independent registered public accounting firm for fiscal 2025.
Advisory vote to approve named executive officer compensation.
Approval of amendment to the 2022 Stock Incentive Plan to increase shares by 600,000.
Provision to conduct any other business properly brought before the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director nominees and compensation matters.
Latest events from Daré Bioscience
- Q2 net income hit $12.9M on royalty sale, but liquidity and future losses remain concerns.DARE
Q2 20241 Feb 2026 - Q3 net loss narrowed, major funding secured, but liquidity risks and capital needs persist.DARE
Q3 202413 Jan 2026 - Sildenafil cream to launch via 503B in Q4 2025; pipeline advances amid funding and enrollment shifts.DARE
Q4 202426 Dec 2025 - Shareholders will vote on director elections, auditor ratification, executive pay, and a stock plan amendment.DARE
Proxy Filing2 Dec 2025 - Annual meeting adjourned for lack of quorum; reconvenes July 9, 2025, with unchanged proposals.DARE
Proxy Filing2 Dec 2025 - Up to 2.75M shares registered for resale to fund R&D, with potential for significant dilution.DARE
Registration Filing29 Nov 2025 - Net loss narrows, but liquidity risks persist as revenue from new products is targeted for Q4 2025.DARE
Q1 202526 Nov 2025 - Sildenafil cream and Ovaprene advance, with revenue and key milestones expected in 2024.DARE
Jones Healthcare and Technology Innovation Conference 202525 Nov 2025 - Q2 2025 saw a $4.0M net loss, improved liquidity, and DARE to PLAY set for Q4 launch.DARE
Q2 202523 Nov 2025